Characterization of HER2-Low Breast Tumors among a Cohort of Colombian Women.
Ontology highlight
ABSTRACT: HER2-low tumors have shown promise in response to antibody-drug conjugates (ADCs) in recent clinical trials, underscoring the need to characterize this group's clinical phenotype. In this study, we aimed to explore the clinicopathological features, survival rates, and HER2 amplicon mRNA expression of women affected with HER2-low breast cancer, compared with HER2-negative and HER2-positive groups. We included 516 breast cancer patients from Colombia, for whom we compared clinicopathological features, mRNA expression of three HER2 amplicon genes (ERBB2, GRB7 and MIEN1), survival and risk of mortality between HER2-low cases (1+ or 2+ with negative in situ hybridization (ISH) result) with HER2-positive (3+ or 2+ with positive ISH test) and HER2-negative (0+) cases. A higher propo
SUBMITTER: Rey-Vargas L
PROVIDER: S-EPMC11430567 | biostudies-literature | 2024 Sep
REPOSITORIES: biostudies-literature
ACCESS DATA